Evidence map›Paper›PMID 39596363›Full record

ArticleInternational journal of molecular sciences2024

Comparison Length of Linker in Compound for Nuclear Medicine Targeting Fibroblast Activation Protein as Molecular Target.

Kentaro Hisada, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Yuichiro Kadonaga, Atsuko Saito, Tadashi Watabe, Sifan Feng, Kazuhiro Ooe, Xiaojie Yin, Hiromitsu Haba and 5 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kentaro HisadaRadiation Biological Chemistry, MS-CORE, Forefront Research Center, Graduate School of Science, Osaka University, 1-1 Machikaneyama-cho, Toyonaka 560-0043, Osaka, Japan.
Kazuko Kaneda-NakashimaRadiation Biological Chemistry, MS-CORE, Forefront Research Center, Graduate School of Science, Osaka University, 1-1 Machikaneyama-cho, Toyonaka 560-0043, Osaka, Japan.ORCID 0000-0001-6657-5059
Yoshifumi ShirakamiInterdisciplinary Research Center for Radiation Sciences, Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita 565-0871, Osaka, Japan.ORCID 0000-0003-2352-9057
Yuichiro KadonagaInterdisciplinary Research Center for Radiation Sciences, Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita 565-0871, Osaka, Japan.
Atsuko SaitoResearch Center for Ultra-High Voltage Electron Microscopy, Osaka University, 7-1 Mihogaoka, Ibaraki 567-0047, Osaka, Japan.
Tadashi WatabeDepartment of Radiology, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Osaka, Japan.ORCID 0000-0001-8658-2395
Sifan FengRadiation Biological Chemistry, MS-CORE, Forefront Research Center, Graduate School of Science, Osaka University, 1-1 Machikaneyama-cho, Toyonaka 560-0043, Osaka, Japan.
Kazuhiro OoeRadioisotope Research Center, Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita 565-0871, Osaka, Japan.ORCID 0000-0002-8560-027X
Xiaojie YinNishina Center for Accelerator-Based Science Nuclear Chemistry Group, RIKEN, 2-1 Hirosawa, Wako 351-0198, Saitama, Japan.
Hiromitsu HabaNishina Center for Accelerator-Based Science Nuclear Chemistry Group, RIKEN, 2-1 Hirosawa, Wako 351-0198, Saitama, Japan.
Masashi MurakamiInterdisciplinary Research Center for Radiation Sciences, Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita 565-0871, Osaka, Japan.ORCID 0000-0001-7936-2263
Atsushi ToyoshimaInterdisciplinary Research Center for Radiation Sciences, Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita 565-0871, Osaka, Japan.
Jens CardinaleNuclear Medicine Department, University Hospital Düsseldorf, Moorenstraße 5 Universitätsklinikum, 40225 Düsseldorf, Germany.ORCID 0000-0001-6558-966X
Frederik L GieselNuclear Medicine Department, University Hospital Düsseldorf, Moorenstraße 5 Universitätsklinikum, 40225 Düsseldorf, Germany.
Koichi FukaseInterdisciplinary Research Center for Radiation Sciences, Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita 565-0871, Osaka, Japan.ORCID 0000-0001-8844-0710

Funding

JSPS KAKENHI JP24K02404, JP23K06049Osaka University the Drug Discovery Science Division of the Institute for Open and Transdisciplinary Research Ini-tiatives (OTRI)
6 · The paper itself

Abstract

Novel nuclear medicine therapeutics are being developed by labeling medium-molecular-weight compounds with short-lived alpha-emitting radionuclides. Fibroblast activation protein α (FAPα) is recognized as a highly useful molecular target, and its inhibitor, FAPI, is a compound capable of

Indexed as

EndopeptidasesMembrane ProteinsAnimalsAstatineCell Line, TumorFibroblast Activation Protein AlphaGelatinasesHumansMiceMolecular Targeted TherapyNuclear MedicineRadiopharmaceuticalsSerine EndopeptidasesAstatineEndopeptidasesFibroblast Activation Protein AlphaGelatinasesMembrane ProteinsRadiopharmaceuticalsSerine EndopeptidasesAt-211FAPIFAPαmiddle moleculenuclear medicine

Identifiers

PMID39596363
PMCPMC11594969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.